Scientific societies and Biomedical Research

Fausto J. Pinto, MD, PhD, FESC President-Elect ESC



Faculdade de Medicina Universidade de Lisboa

Rome Cardiology Forum 2014 An ESC Update Programme in Cardiology

Rome, January, 29-31 2013 Università Cattolica del Sacro Cuore Conference Center Europa









Faculdade de Medicina Universidade de Lisboa

Cardiovascular disease is the # 1 cause of death worldwide and will remain for the next 20 years

Disease or injury	2002 Ranking	2030 Ranking	Change in rank
		(projected)	
Ischemic heart disease	1	1	0
Cerebrovascular disease	2	2	0
Lower respiratory infection	3	5	-2
HIV/AIDS	4	3	+1
COPD	5	4	+1
Perinatal conditions	6	9	-3
Diarrheal diseases	7	16	-9
Tuberculosis	8	23	-15
Trachea bronchus, lung cancers	9	6	+3
Road traffic accidents	10	8	+2
Diabetes mellitus	11	7	+4

Mathers CD, et al. PLoS Med. 2006;3:2011-2030. Elveback LR, et al. Mayo Clin Proc. 1986;61:896-900.

Figure 1. Distribution of global NCD by cause of death, both sexes





(Source: WHO, 2008b)

Cardiovascular Disease – The Problem

- CVD kills 2 million European citizens each year, more than all cancers combined
- Costs €192,000,000,000
- CVD mortality is reducing in some countries but overall the problem is worsening, with increasing obesity, an unhealthy work force and an ageing population
- W-E gradient with an inverse relation between need and resourced







Age standardised CHD mortality rates (under 65) in men & women





Health at a Glance Europe 2012













Health at a Glance 2011 OECD INDICATORS

- Looking back at the evolution of health and health systems since the OECD was created in 1961, three major trends stand out:
 - 1. The remarkable gains in life expectancy.
 - 2. The changing nature of risk factors to health.
 - 3. The steady growth in health spending, which has exceeded GDP growth by a substantial amount.



Life expectancy at birth, 2009 (or nearest year available), and years gained since 1960

Life expectancy at birth, 2009

Years gained, 1960-2009



Source: OECD Health Data 2011.

ROPEAN SUCIETY OF CARDIOLOGY®

1.3.1 Ischemic heart disease, mortality rates, 2009 (or nearest year)

1.3.2 Stroke, mortality rates, 2009 (or nearest year)

	Females	Males		Females	Males
Korea	21 37				
Japan	17 38		Israel	23 28	
France	19 50		Switzerland	25 29	
Portugal	29 54		France	22 31	
Netherlands	62			29 32	
Spain	28 66		Vallaua	29 34	
İsrael	43 78		Nethenanus	32 35	
Chile	39 81		Austria		
Italy	41 81		Austria	28 30	
Luxembourg	<u> </u>		loolond	32 39	
Norway	42 87		Spain	30 41 	
Switzerland	42 88		lraland	- 26 41	
Slovenia	40 89		Norway	- 21 42	
Greece	<u> </u>		United Kingdom		
Denmark	49 93		New Zealand		
Belgium	42 94		Sweden		
Australia	52 99		Belaium	- 38 45	
Mexico	65 103		Mexico		
Germany	56 110			37 48	
Iceland	50 110		Finland	38 50	
United Kingdom	50 110		Italv	40 50	
OECD	60 117		.lapan	30 53	
Sweden	58 118		OECD	42 54	
Canada	61 123		Denmark	45 56	
Austria	67 124		Chile	47 66	
United States	68 129		Greece	69 70	
New Zealand	70 131		Korea	46 73	
Ireland	65 137		Slovenia	54 76	
Poland	66 139		Estonia	52 80	
Finland	74 170		Portugal	62 81	
Czech Republic	126 207		Czech Republic	68 84	
Hungary	156	275	Poland	62 88	
Estonia	141	282	Hungary	71 111	
Slovak Republic	208	324	Slovak Republic	77 112	
Russian Federation	269	// 524	Russian Federation	230	// 313
	0 50 100 150 200 2	250 300 350		0 50 100	150 200 250 200
	Age-standardised rates per 1	00 000 population		And atopdated	and rates per 100 000 membrin
				Age-standardi	seu rates per 100 000 population

Source: OECD Health Data 2011; IS-GBE (2011).

Source: OECD Health Data 2011; IS-GBE (2011).

StatLink ms= http://dx.doi.org/10.1787/888992529367*

EUROPEAN

Decline in Deaths from Cardiovascular Disease in Relation to Scientific Advances.



Nabel EG, Braunwald E. N Engl J Med 2012;366:54-63



Increasing obesity rates among the adult population in OECD countries, 1990, 2000 and 2009 (or nearest years)







StatLink ms http://dx.doi.org/10.1787/888932523215





7.1.1 Total health expenditure per capita, public and private, 2009 (or nearest year)

EUROPEAN SOCIETY OF CARDIOLOGY®

Life expectancy and health care spending The global picture





What is the role of Scientific Societies, such as ESC?

How to help shaping the future of Cardiovascular Medicine?



ESC Structure



85 000 members



Prof. Fausto Pinto, FESC ESC President Elect EUROPEAN SOCIETY OF CARDIOLOGY®

Our roots are European Our reach is global

National Cardiac Societies

- 56 National Cardiac Societies from Europe and the Mediterranean
- Benefit from ESC membership and the European Membership Card
- Active participation in the ESC activities including the ESC Congress
- 38 Affiliated Cardiac Societies outside Europe and the Mediterranean area





Prof. Fausto Pinto, FESC ESC President Elect

Role of Scientific Societies

- Grants (Research and Training)
- Registries/Research
- Educational Activities
- Guidelines and standards
- Advocacy and lobbying



Challenges for health research in Europe

- **Growing prevalence** of chronic diseases
- A declining labour force
- Rising healthcare costs
- A fragmented community of innovators



• Inadequate research coordination at national, regional and EU level



Benefit of funding CV Research

- An investment of \$3.70 per American citizen per year has meant that a million premature deaths have been avoided in the United States alone (Zerhouni EA Science 2006)
- The average life expectancy of patients with coronary heart disease has increased by 3 years since 1970 owing to research in that field, as well as other factors such as change in lifestyle and disease prevention (Sipido K CV Res 2009).



Funding Research

- Barcelona Declaration (2002): to gradually increase the share that the EU dedicates to research and development (R&D) to 3% of its gross domestic product (GDP) by 2010.
- <u>Currently</u> the EU budget for research amounts to only 1.8% of its GDP.



Funding Research

- <u>United States (US):</u> 2.7%
- <u>Japan:</u> 3.4%,
- <u>China</u>: 160% increase in investment in R&D between 2002 and 2007, representing 1.75% of GDP, and a plan to increase to 2.2% of GDP by 2015



Funding for CV Research

 Framework Programme 7 (FP7), the main European Programm for Research Grants, received <u>6 billion</u> <u>Euros</u>, some 10% of the total 2008– 2013 research budget.





FP7 funding for CVD research in 2007-2012



Number of projects: **317** Total Costs : € 960 million EC Contribution : € **732 million**

EC Contribution				
€ 586 M	100			
€ 84 M	45			
€ 62 M	172			
	tribution € 586 M € 84 M € 62 M			





FP7 funding for CVD research in 2007-2012 adjusted for population



Number of projects: **318** Total Costs : € 968 million EC Contribution : € **738 million**

EC Cont	Projects		
COOPERATION IDEAS PEOPLE	€ 586 M € 84 M € 62 M	100 45 172	
0 0,01 - 0,12 0,12 - 0,22			





Health Research in FP7 2007 - 2013

Commission



Funding for CV Research

- Framework Programme 7 (FP7), the main European Programm for Research Grants, received <u>6 billion</u> <u>Euros</u>, some 10% of the total 2008– 2013 research budget.
- Horizons 2020 has a total budget of 79 billion Euros. Health will have about 10 bilion euros for 2014-20.





Recearch and

Horizon 2020 - the next EU HORIZON 2020 Framework programme for Research

and Innovation (2014-2020) Three priorities **Excellent** Societal science challenges Industrial leadership

Action lines: Spreading Excellence and Widening **Participation** Science with and for Society

Budget: ~ €79 billion

- **Major simplification:** single set of rules
- More support for innovation activities
- Strong focus on creating business opportunities
- Focus on societal challenges





Research and

The Health challenges ahead

- Chronic and degenerative diseases gain importance in the context of the ageing population
- More than 70% of healthcare spending on chronic diseases
- Wanted: ways of keeping our healthcare costs stable and our healthcare systems running
- EU must catch up with global health innovation leaders and keep its biomedical industry





Horizon 2020 and the Health, Demographic change and wellbeing

- 1. Understanding health, aging and disease
- 2. Improving diagnosis
- 3. Innovative treatments and technologies
- 4. Advancing active and healthy ageing
- 5. Integrated, sustainable, citizen-centred care
- 6. Improving health information and data exploitation
- 7. Coordination of national activities/participation in international initiatives



In the pipeline: public-private partnership for innovative health research

- Based on the successes of the Innovative Medicines Initiative (IMI)
- Mission: create an even more powerful research and innovation machine – with broader objectives and a wider range of activities and partners
- Legislative proposal just has been put forward for the inter-institutional agreement
- IMI2 Strategic Research Agenda is currently under consultations



Funding for CV Research

- Framework Programme 7 (FP7), the main European Programm for Research Grants, received <u>6 billion Euros</u>, some 10% of the total 2008–2013 research budget.
- Horizons 2020 has a total budget of 79 billion Euros. Health will have about 10 bilion euros for 2014-20.
- The <u>National Institutes of Health (NIH)</u> budget was approximately <u>\$30 billion</u> in 2013, with about <u>\$3 billion directed toward the NHLBI</u>, the institute most directly involved with cardiovascular research.



The NIH Almanac-Appropriations 201

Funding for CV Research





www.escardio.org

Prof. Panos Vardas, FESC ESC President

Scientific Societies and Research Financing

Netherlands, where the Netherlands Heart Foundation awards more funding to cardiovascular research than the Netherlands Organisation for Scientific Research, the government agency which funds research.⁸ In the United Kingdom, the British Heart Foundation funds 55% of all cardiovascular research, which is equivalent to an investment of $\pounds 50$ million per year, including full salary of 27 researchers and around 600 research projects worth between £100 000 and £250 000 over a 3-year period.⁶ The National Heart Foundation of Australia provides around \$7.5 million to cardiovascular research every year, and from 2001 to 2005 it increased its investment by 27%, owing to the backing of several sponsors (many of them pharmaceutical companies).¹⁰ In





ESC Training & Research Grants Introduction

To help cardiologists and medical/science graduates under 36 years to acquire research and training experience in European centres of Excellence

Some Grants or Fellowships concern specific topics of Cardiology and eligibility criteria may differ between them

www.escardio.org/grants



ESC Training Grants

Application/Awardees evolution over the past 10 years





Awarded





Prof F. Pinto, FESC ESC President-Elect

ESC Research Grants

Application/Awardees evolution over the past 7 years









www.escardio.org

Prof F. Pinto, FESC ESC President-Elect

Special article

Evolution and Scientific Impact of Research Grants From the Spanish Society of Cardiology and Spanish Heart Foundation (2000-2006)

Rafael Aleixandre Benavent,^{a,*} Adolfo Alonso Arroyo,^{a,b} Manuel Anguita Sánchez,^c Máxima Bolaños Pizarro,^{a,b} Magda Heras,^c Gregorio González Alcalde,^{a,b} Carlos Macaya Miguel,^c Carolina Navarro Molina,^{a,b} Lourdes Castelló Cogollos,^a Juan Carlos Valderrama Zurián,^{a,b} Francisco Javier Chorro Gascó,^c Vicente Bertomeu Martínez,^c María Jesús Salvador Taboada,^c Leandro Plaza Celemín,^c Julián Pérez-Villacastín,^c Ángel Cequier Fillat,^c Alfonso Varela Román,^c Eva Laraudogoitia Zaldumbide,^c and Salvador Morell Cabedo^c

Rev Esp Cardiol. 2011;64(10):851-852

Editorial

Scientific Societies and Biomedical Research

Sociedades científicas e investigación biomédica

Fausto J. Pinto*



Special article

Evolution and Scientific Impact of Research Grants From the Spanish Society of Cardiology and Spanish Heart Foundation (2000-2006)

Rafael Aleixandre Benavent,^{a,*} Adolfo Alonso Arroyo,^{a,b} Manuel Anguita Sánchez,^c Máxima Bolaños Pizarro,^{a,b} Magda Heras,^c Gregorio González Alcalde,^{a,b} Carlos Macaya Miguel,^c Carolina Navarro Molina,^{a,b} Lourdes Castelló Cogollos,^a Juan Carlos Valderrama Zurián,^{a,b} Francisco Javier Chorro Gascó,^c Vicente Bertomeu Martínez,^c María Jesús Salvador Taboada,^c Leandro Plaza Celemín,^c Julián Pérez-Villacastín,^c Ángel Cequier Fillat,^c Alfonso Varela Román,^c Eva Laraudogoitia Zaldumbide,^c and Salvador Morell Cabedo^c

Conclusions: During the period 2000 to 2006, the *Sociedad Española de Cardiología/Fundación Española del Corazón* (Spanish Heart Foundation) provided about €500 000 per year to fund research grants, thereby contributing to the fight against cardiovascular diseases. Almost 60% of grants have led to publications, 73% of which were published in international journals, and 91.34% in national or international journals with an impact factor in the Journal Citation Reports.



Annual Evaluation of the number of grants with and without publication



R. Aleixandre Benavent et al. / Rev Esp Cardiol. 2011;64(10):904-915



ESC CARDIOLOGISTS OF TOMORROW

ESC Cardiologists of Tomorrow Exclusive partnerships

Partnership with ESC National Cardiac Societies: 25 young national groups 25 free registrations offered to each NCS & ACS to attend ESC Congress: selection of candidates made by each country



Initiative led by a nucleus of 7 members from 7 different countries working closely with their National Cardiac Societies and involved in ESC committees

2 sub-specialties groups part of ESC Cardiologists of Tomorrow:





ESC Cardiologists of Tomorrow





JOIN US!

- 25 ESC National young groups
- EACVI Club 35 (echocardiographers)
- Young EAPCI (interventionalists)

Network with young cardiologists all over Europe

Educational opportunities Webinars (*special package for young cardiologists*), ESCeL platform, ESC Clinical Practice Guidelines & more...

ESC Congress: specific scientific sessions, networking, awards & 25 free registrations offered per NCS

ESC Grants, awards and certifications



www.escardio.org/communities/cardio-tomorrow



Role of Scientific Societies

- Grants (Research and Training)
- Registries/Research
- Educational Activities
- Guidelines and standards
- Advocacy and lobbying

EUR*Observational* Research Programme

2009-2013

- 15 different registries
- more than 1 000 Centres
- more than 50 000 patients
- more than 100 publications from EHS/EORP
- Today 63 countries are already participating in

at least one study

Statistical analyses at EHH







EUR*Observational* Research Programme

Current and future re	egistries			PULMONARY HT IN ADULTS (Congenital Disease)
PREVENTION to assess cardiovascular risk factor			ELECTRa (EHRA)	ELECTRa (EHRA)
prevention measures.			EUROASPIRE IV (EACPR)	EUROASPIRE IV (EACPR)
SPECIAL to assess orphan			A FIB GENERAL Pilot	A FIB GENERAL Long-Term
and rare or highly demanding diseases (i.e. bad outcome, high costs,			CARDIOMYOPATHIE S Pilot	CARDIOMYOPATHIES Long-Term
complex management).			CHRONIC ISCHEMIC CVD Pilot	CHRONIC ISCHEMIC CVD Long-Term
development and impact of		TCVT Pilot	TCVT Pilot	TCVT Long-Term
and diagnostic procedures.	A FIB ABLATION Pilot	A FIB ABLATION Pilot	A FIB ABLATION Long-Term	A FIB ABLATION Long-Term
GENERAL to assess the management of diseases,	PREGNANCY & HEART DISEASE I	PREGNANCY & HEART DISEASE I	PREGNANCY AND CARDIAC DISEASE (ROPAC)	PREGNANCY AND CARDIAC DISEASE (ROPAC)
the incidence of which have a major impact.	HEART FAILURE Pilot	HEART FAILURE Long-Term	HEART FAILURE Long-Term + PPCM	HEART FAILURE Long-Term + PPCM
	2010	2011	2012	2013



A survey of European cardiovascular research landscape

Home

About

Funding Database

News Contact us

You are here: Home

Welcome to Cardioscape Project summary CardioScape (" A Survey of the European cardiovascular research landscape and recommendations for future research strategy "), is an 18-Project type: Coordination month project funded by the European Union FP7 research programme. and Support Action CardioScape aims to outline the current CVD research and innovation landscape across Start date: 1 November 2012 Europe towards establishing the extent of duplication across national research programmes End date: 30 April 2014 and the existence of gaps that reduce opportunities for innovation. Grant agreement no: 306086 EU Contribution: 487,365.00 EUR Scientific coordinator: Professor David Wood Partners

Terms & Conditions Privacy Policy Contact us

Copyright @ European Society of Cardiology 1997 - 2013 - All rights reserved



EUROPEAN SOCIETY OF CARDIOLOGY®

Role of Scientific Societies

- Grants (Research and Training)
- Registries
- Educational Activities
- Guidelines and standards
- Advocacy and lobbying





Thank you for attending the ESC Congress 2013 in Amsterdam!

See you next year in **Barcelona** 30 Aug - 3 Sept



ESC CONGRESS

BARCELONA 2014



www.escardio.org

Prof. Fausto Pinto, FESC ESC President Elect

ESC Specialty Congresses



Cardiac Imaging 11-14 December 2013 Istanbul - Turkey



EuroHeartCare 04-05 April 2014 Stavanger - Norway



EuroPRevent 2014 08-10 May 2014 Amsterdam-Netherlands



Heart Failure 2014 17-20 May 2014 Athens-Greece



Basic Science 04-06 July 2014 Barcelona - Spain



www.escardio.org

Prof. Fausto Pinto, FESC ESC President Elect

ESC Scientific Activities

International ESC educational courses built around a global network of international partnerships



- To meet non-European demand for ESC science and knowledge
- To build closer relationships with international organisations
- To extend the ESC mission beyond European borders
- 2011 programme includes Argentina, Asia-Pacific (Malaysia), Brazil, China, India, Mexico and Saudi Arabia



ESC Scientific Activities

Educational Courses





- High quality medical educational programmes covering a variety of key topics
- Aim: high standard and uniformity in training for all European Cardiologists
- Encourage Continuing Medical Education



ESC JOURNAL FAMILY: 9 journals



CARDIOLOGY[®]

www.escardio.org

Prof. Fausto Pinto, FESC ESC President Elect

ESC Scientific Tools

ESC eLearning (ESCeL Platform): the future of sub-specialty cardiovascular training

- New educational platform launched at the ESC Congress 2012
- Online training & self-assessment
- Rich relevant training
- Interaction with national sub-specialty societies and local trainers



MISSION STATEMENT

"The highest European standard of training and education, to as many as possible, at the lowest cost possible"



ESCel – ESC eLearning platform

Discover it now at: http://learn.escardio.org/default.aspx





Role of Scientific Societies

- Grants (Research and Training)
- Registries
- Educational Activities
- Guidelines and standards
- Advocacy and lobbying



ESC Guidelines with the whole family of educational products



SOCIETY OF CARDIOLOGY®



National Guidelines Coordinators Role and Missions

		С	linical Practice	Guidelines	National Guidelines Coordinators You can find all the information you need regarding the National Guidelines Coordinators, their role, involvement		
		> Gi	uidelines endorse	ement			
		Li	st of ESC Practice	Guidelines			
		Ab	About ESC Guidelines		The role of the ESC Guidelines Coordinator is to coordinate and communicate with its National Society		
		ES	ESC Guidelines Publication		translations and implementation of the ESC Clinical Practice Guidelines.		
Clinical Practice Guidelines	Clinical Practice Guidelines Guidelines endorsement						
Guidelines endorsement							
List of ESC Practice Guidelines	You will find below the National Guidelines Coordinator names classified by Countres.			c3.	The core mission of the National Guidelines Coordinator is to:		
About ESC Guidelines	For more information on their role and activities.			N	N Participate in the energy I Coo opportuging of the State State State day the Soo of mining Participa		
ESC Guidelines Publication	Countries	Names	Countries	Names	Guidelines.		
Cuidelines and mart	Albania	Ahmet Kamberi	Lebanon	Georges Saade	>> Help with the selection of national experts to be involved in the review process of future ESC Clinical		
Guidelines endorsement	Armenia	Parounak Zelveian	Libyan Arab Jamahiriva	Ben Lamin Hisham	Practice Guidelines.		
Scientific Statements	Austria	Irene Lang	Lithuania	Rimvydas Slapikas	» Be active in the endorsement and possble translation processes of the ESC Clinical Practice		
Guidelines Implementation	Belarus	Irina Lazareva	Luxembourg	Louis Bosante	Guidelines.		
Guidelines Products	Belgium	Marc Cleys	Macedonia	Elisabeta Srbinovska-Kotovska	Coordinate with its National Society of Cardiology the decision to officially endorse the ESC Clincial Practice		
Pocket Guidelines for iPhone and Smartphone	Bosnia & Herzegovina	Mirza Dilic	Malta	Terence Tilney	Guidelines as well as their possible translations.		
	Bulgaria	Elina Trendafilova	Moldave (Rep.of)	Mihail Popovici	Opending to the completion 9 return of the endergoment forms which are switchle form the 500 Web Other		
Highlight On	Croatia	Milo Bergovec	Могоссо	Halima Benjelloun	Coordinate the completion & return of the endorsement forms which are available from the ESC web Site.		
Stor 10 hu	Croatia	Bosko Skoric	Netherlands	Liselot van Erven			



www.escardio.org

Translations of ESC Guidelines by NCS on ESC Website

List of ESC Practice Guidelines About ESC Guidelines Topics: Congenital Heart Disease ESC Guidelines Publication Schedule Guidelines Products Guidelines Implementation Guidelines for iPhone and Smartphone Highlight On Highligh	Clinical Practice Guideline	s	Grown-Up Con	genital Heart Disea	se (Management of)		4
About ESC Guidelines Topics: Congenital Heart Disease ESC Guidelines Publication Current versions available to download Guidelines endorsement Image: Constraint on the statements on the statement on the	List of ESC Practice Guideli	nes					
ESC Guidelines Publication Guidelines endorsement Scientific Statements Guidelines Implementation Guidelines Products Pocket Guidelines for iPhone and Smartphone ESC Congress information Highlight On	About ESC Guidelines	0	Topics: Congenital H	Topics: Congenital Heart Disease			
Guidelines endorsement Image: Constraint of the state of the st	ESC Guidelines Publication Schedule		Current versions ava	ailable to download			
Scientific Statements 2010 Image: Full Text European Heart Journal (31); 29152957 - doi:10.1093/eurheartij/ehq249 2 MB 2 MB Guidelines Implementation Image: Pocket guidelines Compendium of Abrdiged ESC Guidelines 2 MB 2 MB </td <td>Guidelines endorsement</td> <td>0</td> <td>Publication date</td> <td>Versions</td> <td>References</td> <td>Size</td> <td></td>	Guidelines endorsement	0	Publication date	Versions	References	Size	
Guidelines Implementation Guidelines Products Pocket Guidelines for iPhone and Smartphone ESC Congress information Highlight On Current translated versions available to download: Choose your language Highlight On	Scientific Statements	0	2010	😲 Full Text	European Heart Journal (31); 2915– 2957 - doi:10.1093/eurhearti/ehq249		2 MB 🔀
Guidelines Products Pocket Guidelines for iPhone and Smartphone ESC Congress information Highlight On Current translated versions available to download: Choose your language Highlight On	Guidelines Implementation	ı		IG Pocket guidelines			
Pocket Guidelines for iPhone and Smartphone ESC Congress information Highlight On Urrent translated versions available to download: Choose your language Highlight On Urrent translated versions available to download: Choose your language Lithers	Guidelines Products			FG Pocket guidelines	Compendium of Abrdiged ESC Guidelines		
and Smartphone ESC Congress information Highlight On Highlight On Luthors Lut	Pocket Guidelines for iPho	ne		📮 Pda	Download the PDA Version		
ESC Congress information ESC Congress information CME Questions - GUCH Current translated versions available to download: Choose your language Highlight On Authors Translations available here EUROPEA	and Smartphone			§ Slideset	GUCH Educational Slide set		11 MB 🌉
Highlight On Current translated versions available to download: Choose your language Translations available here	ESC Congress information			€ CME Questions	CME Questions - GUCH		
Highlight On Translations available here			Current translated v	ersions available to dowr	load: Choose your language 💌		
Translations available here	Highlight On	_					
here			A 4		Translations avail	able	
EUROPEA					here		
	www.oscardio.org						EUROPEAN

Role of Scientific Societies

- Grants (Research and Training)
- Registries
- Educational Activities
- Guidelines and standards
- Advocacy and lobbying



ESC Advocacy Activities

The ESC reaches out to audiences outside the cardiology community:

- EU and National Policy Makers
- NGOs and Professional Societies
- Health Care Industry



ESC European Affairs

The ESC works to take forward the European agenda on:

- Prevention
- Research
- Regulatory affairs
- Registries
- e-Health





www.escardio.org/about/what/advocacy



European Heart Health Charter: why?

REDUCE BURDEN of cardiovascular

disease in Europe

REDUCE INEQUALITIES within and between countries

MOBILISE COLLABORATION

political, economic & social, beyond national boundaries

→ Unite forces against Europe's greatest killer







Adopted by 30 countries in Europe







Brazilian Society of Cardiology "Letter from Rio" III Brazil Prevent / I Latin American



www.escardio.org/EACPR

ESC Brussels Ofice- Square de Meeus





EUROPEAN HEART AGENCY OF THE ESC The 3 Axes - activities

Advocacy/EU affairs	European Heart Health Institute	European Heart Academy
Cardio-policy	CardioScape	Accreditation
BioMed Alliance	Dynamic Portal	Certification
Chronic Disease	Quality Assessment	Revalidation
Alliance	Clinical	Harmonisation of
MEP Heart Group	trials/Observational	post-graduate
Platform for	Studies	education
dissemination of	Research	CPD
funding	Economics & Health	Universities joint
opportunities	Care	projects
towards CV	Personalised	
community	Medicine	

Novel Technologies

The organization of Cardiology in the next future: the role of Scientifc Societies

- Promote continuous medical education
- Define standards
- Support the development of national and transnational research projects
- Improve the knowledge about local and regional realities
- Monitor and assess how research support translates into results (return on investment)
- Be the voice of the scientific community (regulators, governments, etc) and the patients



Thank you!

On behalf of the ESC, I wish you all a very successful Course



www.escardio.org

Prof. Fausto Pinto, FESC ESC President Elect